The Impact of Fish Oil Supplementation on the Outcome of Children with Pneumonia I
Status
Conditions
Treatments
Details and patient eligibility
About
The aim of study is to investigate the effect of enteral feeding of Omega-3 on the outcome of children with Pneumonia in PICU
Full description
Group A(cases) will be supplemented by omega-3 fatty acids for immediate post admission consecutive 7 days besides conventional treatment of pneumonia, in a dose of 350 mg twice daily for children less than 3 years and 450 mg twice daily for older children according to the standard treatment per the American Institute of Medicine of the National Academies guidelines for maximum dose for this age group. (Institute of Medicine of the National Academies,2016)
Side effects of omega-3 supplements are usually mild. They include unpleasant taste, bad breath, bad-smelling sweat, headache, and gastrointestinal symptoms such as heartburn, nausea, and diarrhea. (Office of Dietary Supplements ,2016)
Group B(controls) will be received enteral feeding without omega-3 fatty acid support.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
- All children patients with severe pneumonia admitted to PICU
- Both sexes
- Age: under 5 years
- Whose parents or caregivers approve for participation in the study
Exclusion Criteria
- Patients with chronic illnesses to exclude bias that could be emerged due to the chronic disease effect
- Whose parents or caregivers will not apply for participation in the study
- Patients who will be contraindicated for enteral feeding
Trial design
Primary purpose
Allocation
Interventional model
Masking
122 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Hoda Atef Abelsattar Ibrahim
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal